文献速递免疫规划卫生政策与健康促进

结核感染结局的不精确性对非劣效疫苗试验的影响

Imprecision in tuberculosis infection outcomes: implications for non-inferiority vaccine trials.
PubMed 文献 · Int J Epidemiol · 2026-01-01

该统计模拟研究评估了结核感染标志物灵敏度和特异度不完美时,对以感染为主要结局的非劣效结核疫苗试验解读的影响。研究模拟了2%、5%和8%三种两年累积感染风险场景,发现当灵敏度和特异度均为95%时,在三种风险场景下错误宣称非劣效的风险分别为96.8%、53.2%和27.8%。

要点

  • 结核感染标志物不完美会偏倚非劣效试验结果,可能错误宣称非劣效。
  • 模拟显示灵敏度和特异度轻度下降即可大幅增加错误宣称非劣效的风险。
  • 设计此类试验时必须考虑感染检测工具的特异度。

核心结论

  • 使用感染为主要结局的结核疫苗非劣效试验必须考虑检测工具特异度,否则可能默认宣称非劣效。

研究设计与样本

  • 统计模拟研究,模拟两臂随机对照非劣效试验,数据生成基于三种两年累积结核感染风险场景(2%、5%、8%)。
  • 假设结核感染检测特异度范围为100%至85%,灵敏度范围为100%至64%。

主要发现

  • 当灵敏度和特异度均为100%时,三种累积风险场景下I类错误和功效均接近预期值(2.5%和80%)。
  • 当灵敏度和特异度均为95%时,在2%、5%和8%累积感染风险场景下,错误宣称非劣效的风险分别为96.8%、53.2%和27.8%。

临床怎么用

  • 在设计和解读以感染为主要结局的结核疫苗非劣效试验时,应评估并考虑检测工具的特异度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomized trials comparing new vaccines against tuberculosis for use in neonates and infants, for whom Bacille Calmette-Guérin vaccination is established practice, are using tuberculosis infection as the primary endpoint in a non-inferiority design. Markers of tuberculosis infection have imperfect sensitivity and specificity. Flaws in the non-inferiority trial design typically bias towards non-inferiority, which may result in falsely declaring non-inferiority. METHODS: We conducted a statistical simulation study to assess the impact of imperfect markers of tuberculosis infection on the interpretation of tuberculosis vaccine trials testing a non-inferiority hypothesis of an infection primary outcome in a two-arm randomized comparison. Data were generated in three 2-year cumulative risk of tuberculosis infection scenarios (2%, 5%, and 8%). The specificity of tests of tuberculosis infection was assumed to range from 100% to 85%, while the sensitivity was assumed to range from 100% to 64%. Log-binomial regression was used to estimate the relative risk of tuberculosis infection. RESULTS: With 100% sensitivity and specificity, type I error and power were both approximately equal to the expected values (2.5% and 80%, respectively) in all three cumulative tuberculosis risk scenarios. With modest deviations from perfect sensitivity and specificity (95% for both), the risk of falsely declaring non-inferiority was 96.8%, 53.2%, and 27.8% in the 2%, 5%, and 8% cumulative tuberculosis risk infection scenarios, respectively. DISCUSSION: Tuberculosis vaccine non-inferiority trials using an infection primary outcome must be designed and interpreted accounting for the specificity of the tools used to measure infection, otherwise they risk declaring non-inferiority by default.

来源:Int J Epidemiol,查看原文。版权归原作者所有。

引用

  1. Grint DJ, White RG, Churchyard G, et al. Imprecision in tuberculosis infection outcomes: implications for non-inferiority vaccine trials. Int J Epidemiol. 2026. PMID: 41782488. doi:10.1093/ije/dyag034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。